{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:54:55Z","timestamp":1792803295372,"version":"4.5.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) is heterogenous on molecular, cellular, tissue, and clinical levels. Although many biomarkers have been described in clinical studies, few have been rigorously mapped to specific molecular pathways, tissue pathologies, and clinical manifestations. A focused assessment of peripheral blood levels of C\u2013C Motif Chemokine Ligand-18 (CCL18) and periostin illustrates how biomarkers can link molecular mediators to clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>CCL18 is produced by pulmonary macrophages in response to type 2 cytokines and IL6. Elevated serum CCL18 is associated with interstitial lung disease (ILD) in SSc patients and is prognostic for ILD progression. It is pharmacologically modulated by IL6 inhibition, and associated with stabilization of lung function decline but not with improvements in skin fibrosis. Periostin is produced by dermal fibroblasts in SSc in response to type 2 cytokines and transforming growth factor-beta. Elevated serum periostin is associated with cutaneous disease in SSc patients but not ILD. Other cell- and tissue-specific biomarkers detectable in peripheral blood and informative with respect to SSc pathogenesis include KL-6 and SP-D in lung epithelium, osteopontin in lung macrophages, and cartilage oligomeric matrix protein in dermal fibroblasts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Blood biomarkers related to specific molecular mediators, cell types, and tissues of origin can help to link therapeutic targets to treatable traits in SSc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000827","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T17:05:06Z","timestamp":1629651906000},"page":"480-485","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment"],"prefix":"10.1097","volume":"33","author":[{"given":"Joseph R.","family":"Arron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/jcm9113388","article-title":"Potential biomarkers in systemic sclerosis: a literature review and update","volume":"9","author":"Utsunomiya","year":"2020","journal-title":"J Clin Med"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd.2016.124","article-title":"Reducing the risk of failure: biomarker-guided trial design","volume":"15","author":"Townsend","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2015.04.006","article-title":"Stratified medicine in inflammatory disorders: from theory to practice","volume":"161","author":"Arron","year":"2015","journal-title":"Clin Immunol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1900\/RDS.2008.5.128","article-title":"The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus","volume":"5","author":"Wieczorek","year":"2008","journal-title":"Rev Diabet Stud"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcdb.2019.12.007","article-title":"Rationally-based therapeutic disease modification in systemic sclerosis: novel strategies","volume":"101","author":"Asano","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta \u2013 at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"eaav5183","DOI":"10.1126\/scisignal.aav5183","article-title":"Specificity, versatility, and control of TGF-beta family signaling","volume":"12","author":"Derynck","year":"2019","journal-title":"Sci Signal"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/cea.12065","article-title":"Role of CCL18 in asthma and lung immunity","volume":"43","author":"Tsicopoulos","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.semarthrit.2020.01.006","article-title":"Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: where do we stand?","volume":"50","author":"Elhai","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/art.22559","article-title":"CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis","volume":"56","author":"Prasse","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1183\/09031936.00131713","article-title":"Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis","volume":"43","author":"Schupp","year":"2014","journal-title":"Eur Respir J"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/art.21257","article-title":"Serum pulmonary and activation-regulated chemokine\/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis","volume":"52","author":"Kodera","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1183\/09031936.00004711","article-title":"Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis","volume":"38","author":"Tiev","year":"2011","journal-title":"Eur Respir J"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41020","article-title":"Progression of interstitial lung disease in systemic sclerosis: the importance of pneumoproteins Krebs von den Lungen 6 and CCL18","volume":"71","author":"Volkmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S2213-2600(18)30185-1","article-title":"Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: posthoc assessment of the CAPACITY and ASCEND trials","volume":"6","author":"Neighbors","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00018-013-1494-y","article-title":"The role of periostin in tissue remodeling across health and disease","volume":"71","author":"Conway","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjd.12117","article-title":"Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis","volume":"168","author":"Yamaguchi","year":"2013","journal-title":"Br J Dermatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1164\/rccm.201510-2032PP","article-title":"Roles of periostin in respiratory disorders","volume":"193","author":"Izuhara","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/cimm.2000.1687","article-title":"Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts","volume":"204","author":"Song","year":"2000","journal-title":"Cell Immunol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"eaba1983","DOI":"10.1126\/sciadv.aba1983","article-title":"Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis","volume":"6","author":"Adams","year":"2020","journal-title":"Sci Adv"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","article-title":"Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","article-title":"Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis","volume":"11","author":"Strunz","year":"2020","journal-title":"Nat Commun"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/imcb.12212","article-title":"IL-6 mediates ER expansion during hyperpolarization of alternatively activated macrophages","volume":"97","author":"Ayaub","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/all.12240","article-title":"Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells","volume":"68","author":"Shoda","year":"2013","journal-title":"Allergy"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jdermsci.2018.02.001","article-title":"Pro-fibrotic phenotype of human skin fibroblasts induced by periostin via modulating TGF-beta signaling","volume":"90","author":"Kanaoka","year":"2018","journal-title":"J Dermatol Sci"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1801130","DOI":"10.1183\/13993003.01130-2018","article-title":"SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)","volume":"52","author":"Raghu","year":"2018","journal-title":"Eur Respir J"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/cells10051104","article-title":"Cytokines involved in the pathogenesis of SSc and problems in the development of anti-cytokine therapy","volume":"10","author":"Shima","year":"2021","journal-title":"Cells"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/ard.2007.086850","article-title":"Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta","volume":"68","author":"Farina","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Investig"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-015-1653-0","article-title":"Cutaneous keratoacanthomas\/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008)","volume":"64","author":"Lacouture","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-beta pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"100140","DOI":"10.1016\/j.xcrm.2020.100140","article-title":"Osteopontin links myeloid activation and disease progression in systemic sclerosis","volume":"1","author":"Gao","year":"2020","journal-title":"Cell Rep Med"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/thoraxjnl-2014-206069","article-title":"Asthma biomarkers: what constitutes a \u2019gold standard\u2019?","volume":"70","author":"Arron","year":"2015","journal-title":"Thorax"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T18:00:22Z","timestamp":1748282422000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000827","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}